Treponema pallidum Vaccines
Creative Biolabs is a professional vaccine development expert with extensive experience in vaccine design, immunogenicity evaluation, safety evaluation, and production process optimization. We have won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects in vaccine development services for Treponema pallidum vaccines. We guarantee the finest results for our customers all over the world.
Treponema pallidum, a member of the Spirochete family, is spread rapidly through close sexual contact in squamous or columnar epithelium. Recent studies suggest that Treponema pallidum is related to various diseases, such as syphilis, bejel, and yaws. The yaw is regarded as a multistage disease endemic in Pacific, South-East Asia, West and Central Africa. This disease mainly occurred in children, which can cause destructive lesions of the skin and soft tissues. Syphilis is a prevalent disease in low- and middle-income countries, which leads to fever, headache, and muscle pains. In this condition, Treponema pallidum has been considered as a Public Health Emergency of International Concern. Studies show that many groups have tried to develop a safe and effective vaccine to prevent Treponema pallidum infection and severe disease. Up to now, various vaccine targets have been developed in Treponema pallidum prevention, which have been proven to be safe and effective in further vaccine research.
Fig.1 The Complete Genome Sequence of Treponema pallidum. (Fraser C.M, et al., 1998)
The Treponema pallidum Vaccines
Treponema pallidum, a motile, gram-negative spirochete, is mainly transmitted by sexual exposure or vertical transmission during pregnancy, which is the leading cause of preventable stillbirths and neonatal death in developing countries. A wide variety of vaccine targets of Treponema pallidum have been studied to develop a novel vaccine to prevent Treponema pallidum and its diseases. Currently, research is urgently needed to understand the underlying causes of Treponema pallidum infections and identify vaccine targets and methods for validation.
The Candidate Targets for Treponema pallidum Vaccines
The Treponema pallidum vaccine should be an effective method for eliminating infections, which could play an important role in disease therapy. Various studies have focused on the identifying and testing the potential vaccine candidates. Meanwhile, we also offer a series of candidate proteins tests for vaccine development in various animal models, including but not limited to, TprK, Tp0750 and Tp0751, as well as TP0136.
- TprK, also known as Treponema pallidum repeat protein K, has been proven to be a potential vaccine component in rabbit models. It is a recombinant peptide which is responsible for eliciting T- and B-cell responses and protects against infection. Results derived from different groups of infected rabbits show it can be recognized by T cells and antibodies during infection and effectively reduce syphilitic lesion development.
- Tp0750 and Tp0751, also known as pallilysin, play an important role in Treponema pallidum dissemination and tissue invasion. The studies show that they can reduce the ability of the host protein for blood coagulation and destroy the basement membrane. Many sequence variations can be detected in Tp0750 and Tp0751, which suggest the diversity of pathogenic and lethal damage. Meanwhile, research also reveal that the binding of pallilysin with their host proteins is associated with the treponemal invasiveness.
- TP0136 is known as an important constituent of the host extracellular matrix, which can be usually found in blood, saliva, and other body fluids. The studies indicate that TP0136 plays an important role in fibronectin (Fn) binding. The sequence variants of TP0136 is related with various Treponema pallidum strains, such as Nichols Houston, Nichols Seattle, Nichols Dallas, Dal-1, MexicoA, Bal73-1, Seattle81-4, and SS14. In addition, TP0136 is highly expressed in rabbit model of Treponema pallidum infection, suggesting TP0136 is a suitable target for development of Treponema pallidum vaccine.
Our Services for Treponema pallidum Vaccines
With a variety of mature and comprehensive platforms and technologies for the evaluation and improvement of vaccine development, we are dedicated to providing the best solutions and protocols customized to vaccines development for Treponema pallidum.
- Fully integrated vaccine services
- Cost-effective vaccine development manner
- Well-established vaccine developing platform
Creative Biolabs is a leader in the field of vaccine development and has focused on the vaccine development services for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.
Reference
- Fraser C.M, et al. (1998). “Complete genome sequence of Treponema pallidum, the syphilis spirochete.” Science. 281(5375), 375-88.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
